Europe
Bordeaux, France, September 05th 2019 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, announced that it has raised €6.2 million via a capital increase and non-dilutive funding.
BioCity, the pioneering life science incubator and business collective, has today announced investment in precision medicine biotech, Kinomica Ltd., via the Innovate UK Precision Medicine Investment Accelerator.
Crescendo Biologics Ltd announces that Stewart Kay has been appointed as the Company’s Chief Business Officer.
Former Ogilvy and WPP executive, David Mayo has joined Verita Healthcare Group, a global provider of preventative, personalised healthcare and wellness clinics, as Group Sales and Marketing Director.
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.
The importance of artificial intelligence and machine learning is ever-increasing in the world of drug development and AstraZeneca is bolstering its participation in the tech revolution by striking a deal with New York-based Schrodinger to use that company’s advanced computing platform to help accelerate drug discovery efforts.
Summit Therapeutics plc presented in vivo proof of concept data for its targeted Enterobacteriaceae antibiotics in animal models of sepsis, pneumonia and urinary tract infection.
Owlstone Medical announced the introduction of a new ReCIVA® Breath Sampler and CASPERTM Portable Air Supply, designed to support internal biomarker discovery programs and those of academic and biopharma clients, and to measure levels of known volatile organic compounds on breath.
Avillion LLP announces the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
PRESS RELEASES